NASDAQ:POAI Predictive Oncology (POAI) Stock Price, News & Analysis $1.06 -0.03 (-2.75%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$1.06 -0.01 (-0.47%) As of 04/25/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock About Predictive Oncology Stock (NASDAQ:POAI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Predictive Oncology alerts:Sign Up Key Stats Today's Range$1.00▼$1.1450-Day Range$0.87▼$1.6952-Week Range$0.55▼$3.06Volume99,300 shsAverage Volume2.36 million shsMarket Capitalization$9.47 millionP/E RatioN/ADividend YieldN/APrice Target$3.00Consensus RatingHold Company OverviewPredictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.Read More… Predictive Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks58th Percentile Overall ScorePOAI MarketRank™: Predictive Oncology scored higher than 58% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingPredictive Oncology has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoveragePredictive Oncology has received no research coverage in the past 90 days.Read more about Predictive Oncology's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Predictive Oncology are expected to grow in the coming year, from ($2.08) to ($0.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Predictive Oncology is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Predictive Oncology is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPredictive Oncology has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Predictive Oncology's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.03% of the float of Predictive Oncology has been sold short.Short Interest Ratio / Days to CoverPredictive Oncology has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Predictive Oncology has recently decreased by 74.57%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPredictive Oncology does not currently pay a dividend.Dividend GrowthPredictive Oncology does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.03% of the float of Predictive Oncology has been sold short.Short Interest Ratio / Days to CoverPredictive Oncology has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Predictive Oncology has recently decreased by 74.57%, indicating that investor sentiment is improving significantly. News and Social Media3.8 / 5News Sentiment1.87 News SentimentPredictive Oncology has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Predictive Oncology this week, compared to 1 article on an average week.MarketBeat Follows2 people have added Predictive Oncology to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Predictive Oncology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.44% of the stock of Predictive Oncology is held by insiders.Percentage Held by InstitutionsOnly 9.04% of the stock of Predictive Oncology is held by institutions.Read more about Predictive Oncology's insider trading history. Receive POAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Predictive Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address POAI Stock News HeadlinesPredictive Oncology develops new approach to identifying viable abandoned drugsApril 16, 2025 | markets.businessinsider.comRenovaro says Predictive Oncology terminated merger agreementApril 5, 2025 | markets.businessinsider.comTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly that, just 12 months later…April 27, 2025 | Paradigm Press (Ad)Predictive Oncology Stock Price, Quotes and ForecastsApril 2, 2025 | benzinga.comPredictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate UpdateApril 1, 2025 | globenewswire.comPredictive Oncology (POAI) Uses AI to Slash Drug Discovery Timelines & Boost Cancer ResearchMarch 27, 2025 | insidermonkey.comPredictive Oncology (POAI) Uses AI to Slash Drug Discovery Timelines & Boost Cancer ResearchMarch 27, 2025 | msn.comTop 8 AI News Updates Driving Markets TodayMarch 25, 2025 | insidermonkey.comSee More Headlines POAI Stock Analysis - Frequently Asked Questions How have POAI shares performed this year? Predictive Oncology's stock was trading at $0.82 on January 1st, 2025. Since then, POAI stock has increased by 29.3% and is now trading at $1.06. View the best growth stocks for 2025 here. How were Predictive Oncology's earnings last quarter? Predictive Oncology Inc. (NASDAQ:POAI) posted its quarterly earnings data on Tuesday, May, 14th. The medical instruments supplier reported ($1.04) earnings per share for the quarter. The medical instruments supplier had revenue of $0.42 million for the quarter. Predictive Oncology had a negative trailing twelve-month return on equity of 286.30% and a negative net margin of 1,012.32%. Read the conference call transcript. When did Predictive Oncology's stock split? Shares of Predictive Oncology reverse split on Monday, April 24th 2023. The 1-20 reverse split was announced on Monday, April 24th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 24th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Predictive Oncology? Shares of POAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Predictive Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Predictive Oncology investors own include Ford Motor (F), Wells Fargo & Company (WFC), Zomedica (ZOM), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), Bank of America (BAC) and Wayfair (W). Company Calendar Last Earnings5/14/2024Today4/26/2025Next Earnings (Estimated)5/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical appliances & supplies Sub-IndustryMedical Equipment Current SymbolNASDAQ:POAI CIK1446159 Webwww.precisiontherapeutics.com Phone(651) 389-4800FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$3.00 Low Stock Price Target$3.00 Potential Upside/Downside+183.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,980,000.00 Net Margins-1,012.32% Pretax Margin-983.62% Return on Equity-286.30% Return on Assets-122.11% Debt Debt-to-Equity RatioN/A Current Ratio1.20 Quick Ratio1.06 Sales & Book Value Annual Sales$1.62 million Price / Sales5.83 Cash FlowN/A Price / Cash FlowN/A Book Value$2.04 per share Price / Book0.52Miscellaneous Outstanding Shares8,932,000Free Float6,438,000Market Cap$9.47 million OptionableNot Optionable Beta1.11 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:POAI) was last updated on 4/27/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Predictive Oncology Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Predictive Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.